Literature DB >> 14500840

Structure-function relationships of the initiation complex of HIV-1 reverse transcription: the case of mutant viruses using tRNA(His) as primer.

Mickaël Rigourd1, Valérie Goldschmidt, Fabienne Brulé, Casey D Morrow, Bernard Ehresmann, Chantal Ehresmann, Roland Marquet.   

Abstract

Reverse transcription of HIV-1 RNA is initiated from the 3' end of a tRNA3Lys molecule annealed to the primer binding site (PBS). An additional interaction between the anticodon loop of tRNA3Lys and a viral A-rich loop is required for efficient initiation of reverse transcription of the HIV-1 MAL isolate. In the HIV-1 HXB2 isolate, simultaneous mutations of the PBS and the A-rich loop (mutant His-AC), but not of the PBS alone (mutant His) allows the virus to stably utilize tRNA(His) as primer. However, mutant His-AC selects additional mutations during cell culture, generating successively His-AC-GAC and His-AC-AT-GAC. Here, we wanted to establish direct relationships between the evolution of these mutants in cell culture, their efficiency in initiating reverse transcription and the structure of the primer/template complexes in vitro. The initiation of reverse transcription of His and His-AC RNAs was dramatically reduced. However, His-AC-GAC RNA, which incorporated three adaptative point mutations, was reverse transcribed more efficiently than the wild type RNA. Incorporation of two additional mutations decreased the efficiency of the initiation of reverse transcription, which remained at the wild type level. Structural probing showed that even though both His-AC and His-AC-GAC RNAs can potentially interact with the anticodon loop of tRNA(His), only the latter template formed a stable interaction. Thus, our results showed that the selection of adaptative mutations by HIV-1 mutants utilizing tRNA(His) as primer was initially dictated by the efficiency of the initiation of reverse transcription, which relied on the existence of a stable interaction between the mutated A-rich loop and the anticodon loop of tRNA(His).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14500840      PMCID: PMC206454          DOI: 10.1093/nar/gkg754

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  58 in total

1.  Interaction between retroviral U5 RNA and the T psi C loop of the tRNA(Trp) primer is required for efficient initiation of reverse transcription.

Authors:  A Aiyar; D Cobrinik; Z Ge; H J Kung; J Leis
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

2.  Dimerization of human immunodeficiency virus (type 1) RNA: stimulation by cations and possible mechanism.

Authors:  R Marquet; F Baudin; C Gabus; J L Darlix; M Mougel; C Ehresmann; B Ehresmann
Journal:  Nucleic Acids Res       Date:  1991-05-11       Impact factor: 16.971

3.  Effects of alterations of primer-binding site sequences on human immunodeficiency virus type 1 replication.

Authors:  X Li; J Mak; E J Arts; Z Gu; L Kleiman; M A Wainberg; M A Parniak
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

4.  Modified nucleotides of tRNA(3Lys) modulate primer/template loop-loop interaction in the initiation complex of HIV-1 reverse transcription.

Authors:  C Isel; R Marquet; G Keith; C Ehresmann; B Ehresmann
Journal:  J Biol Chem       Date:  1993-12-05       Impact factor: 5.157

Review 5.  Interaction of retroviral reverse transcriptase with template-primer duplexes during replication.

Authors:  E J Arts; S F Le Grice
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  1998

6.  A retroviral RNA secondary structure required for efficient initiation of reverse transcription.

Authors:  D Cobrinik; L Soskey; J Leis
Journal:  J Virol       Date:  1988-10       Impact factor: 5.103

7.  Initiation of reverse transcription of HIV-1: secondary structure of the HIV-1 RNA/tRNA(3Lys) (template/primer).

Authors:  C Isel; C Ehresmann; G Keith; B Ehresmann; R Marquet
Journal:  J Mol Biol       Date:  1995-03-24       Impact factor: 5.469

8.  An integration-defective U5 deletion mutant of human immunodeficiency virus type 1 reverts by eliminating additional long terminal repeat sequences.

Authors:  E Vicenzi; D S Dimitrov; A Engelman; T S Migone; D F Purcell; J Leonard; G Englund; M A Martin
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

9.  Reduced replication of human immunodeficiency virus type 1 mutants that use reverse transcription primers other than the natural tRNA(3Lys).

Authors:  A T Das; B Klaver; B Berkhout
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

10.  Functional sites in the 5' region of human immunodeficiency virus type 1 RNA form defined structural domains.

Authors:  F Baudin; R Marquet; C Isel; J L Darlix; B Ehresmann; C Ehresmann
Journal:  J Mol Biol       Date:  1993-01-20       Impact factor: 5.469

View more
  5 in total

1.  Frequent dual initiation in human immunodeficiency virus-based vectors containing two primer-binding sites: a quantitative in vivo assay for function of initiation complexes.

Authors:  Yegor A Voronin; Vinay K Pathak
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

2.  Initiation of HIV Reverse Transcription.

Authors:  Catherine Isel; Chantal Ehresmann; Roland Marquet
Journal:  Viruses       Date:  2010-01-18       Impact factor: 5.818

3.  Importance of A-loop complementarity with tRNAHis anticodon for continued selection of tRNAHis as the HIV reverse transcription primer.

Authors:  Na Ni; Wenqin Xu; Casey D Morrow
Journal:  Virol J       Date:  2007-01-10       Impact factor: 4.099

4.  Heterogeneous structures formed by conserved RNA sequences within the HIV reverse transcription initiation site.

Authors:  Aaron Coey; Kevin Larsen; Joseph D Puglisi; Elisabetta Viani Puglisi
Journal:  RNA       Date:  2016-09-09       Impact factor: 4.942

5.  Extended Interactions between HIV-1 Viral RNA and tRNALys3 Are Important to Maintain Viral RNA Integrity.

Authors:  Thomas Gremminger; Zhenwei Song; Juan Ji; Avery Foster; Kexin Weng; Xiao Heng
Journal:  Int J Mol Sci       Date:  2020-12-23       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.